Breaking News

Financial Report: Anacor Pharmaceuticals

March 15, 2013

Development milestone boost results

Anacor Pharmaceuticals
4Q Revenues: $3.3 million (+27%)

4Q Loss: $12.5 million (loss of $14.5 million 4Q11)

FY Revenues: $10.7 million (revenues were $20.3 million FY11)

FY Loss: $56.1 million (loss of $47.9 million FY11)

Comments: Growth in the quarter was primarily due to the $1.0 million development milestone under a collaboration with Lilly, partially offset by decreases in revenues from our neglected diseases programs. R&D expenses were down 14% to $12.0 million in the quarter.
blog comments powered by Disqus
  • Quality Risk Management

    Quality Risk Management

    Cheryl Abernathy and Bryan Sasbon, Quality Assurance Operations Manager, Ropack Pharma Solutions; QA Director & Regulatory Affairs, Ropack Pharma Solutions||September 8, 2016
    Embracing the process as a means to a strong quality culture

  • Staying Ahead in the Small Molecule Space

    Staying Ahead in the Small Molecule Space

    Dr. Matthew Moorcroft, VP Global Marketing, Cambrex||September 8, 2016
    Understand what is happening in the market and react accordingly

  • FDA & Drug Development

    FDA & Drug Development

    Rachelle Du2019Souza, Regulatory Heights Inc.||September 8, 2016
    You must perform the necessary due diligence to stay on top of regulatory developments